Skip to main content
OpenTrials
Completed

NCT Number: NCT03350516

Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy

The World Health Organization currently recommends that pregnant women in populations with low calcium intake receive daily calcium supplementation (1500 - 2000 mg) divided into three doses which are preferably taken at mealtimes, in addition to daily iron folic-acid supplements. Despite proven efficacy and the WHO recommendation, calcium supplementation in pregnancy is not standard of care in the vast majority of low-income and middle-income countries. Two important barriers to implementation are the cost of the supplements and complexity of the suggested calcium dosing schedule. A lower dose of calcium (500 mg) administered as a single dose has been shown to be beneficial in several trials, and if found to be as effective as the 1500 mg supplementation regimen, it may help overcome these barriers and increase individual and health system adoption.

The Investigators will conduct two parallel, individually randomized, double blind non-inferiority trials in India and Tanzania. Participating pregnant woman will be randomized to either 1500 mg or 500 mg calcium supplementation. The India and Tanzania trials are independently powered for the primary outcomes of i) preeclampsia and ii) preterm birth. The India and Tanzania sites will each enroll 11,000 participants.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

St. John's Research Institute, Bangalore, India

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Nulliparous
  • Attending first ANC visit at study clinics
  • Pregnant women <20 weeks
  • ≥ 18 years old
  • Intending to stay in study area until 6 weeks post delivery
  • Provides informed consent

Exclusion criteria

  • History or signs and/or symptoms of nephrolithiasis
  • Prior diagnosis of parathyroid disorder or thyroidectomy
  • Diseases that require digoxin, phenytoin, or tetracycline therapy

Treatment and study plan

Daily 500 mg elemental calcium as calcium carbonate

Dietary Supplement

Pregnant women in this arm will be provided and counselled to take three tablets, one containing 500 mg elemental calcium as calcium carbonate and 2 placebo supplements daily (total of 500 mg daily). The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Daily1500 mg elemental calcium as calcium carbonate

Dietary Supplement

Pregnant women in this arm will be provided and counselled to take three tablets each containing 500 mg elemental calcium as calcium carbonate daily (total of 1500 mg daily) as currently recommended by the World Health Organization. The supplements in India will also contain 83.3 IU each of vitamin D3, for a total of 250 IU daily. No vitamin D3 will be given in Tanzania.

Primary outcomes

  1. Proportion of pregnant women with incident preeclampsia

    Time frame: Gestational week 20 to Delivery

  2. Proportion of preterm birth

    Time frame: Birth

Sponsors and collaborators

Lead sponsor

Harvard School of Public Health (HSPH)

Other

Collaborators

  • Africa Academy for Public Health
  • Ifakara Health Institute
  • St. John's Research Institute

Registry information

Official study title

Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes

Important dates

Study start
2018
Primary completion
2022
Study completion
2022
First posted
Nov 22, 2017
Registry last updated
Dec 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.